Proximal duodenal bicarbonate secretion is an important factor in humans and animals protecting the mucosa against acidpeptic damage. This study examined the mechanisms responsible for the central nervous system regulation of duodenal bicarbonate secretion by calcitonin gene-related peptide (CGRP) in unrestrained rats. Cerebroventricular administration of rat CGRP significantly inhibited basal duodenal bicarbonate secretion as well as the stimulatory effects of vasoactive intestinal peptide, neurotensin, a luminal PGEI analogue, misoprostol, and hydrochloric acid. The inhibitory effects of cerebroventricular CGRP were abolished by ganglionic blockade with chlorisondamine, significantly attenuated by noradrenergic blockade with bretylium, and enhanced by vagotomy. Inhibition of duodenal bicarbonate secretion induced by CGRP coincided with significant increases in plasma norepinephrine (NE) and vasopressin concentrations. The alpha adrenergic receptor antagonist, phentolamine, and the vasopressin VI receptor antagonist, (1-deaminopenicillamine, 2-[0-methyljTyr, 8-Arg)-vasopressin, given intravenously reversed the central inhibitory effect of CGRP by -50% each. Pretreatment of the animals with both phentolamine and the vasopressin antagonist completely abolished the central inhibitory effect of CGRP. Peripheral vasopressin and NE significantly decreased duodenal bicarbonate secretion, and their inhibitory effects were additive and prevented by phentolamine and the vasopressin antagonist, respectively. We conclude that cerebroventricular CGRP inhibits rat duodenal bicarbonate secretion by activation of sympathetic efferents and subsequent release of NE and vasopressin that act on alpha adrenergic and vasopressin receptors, respectively. (J. Clin. Invest. 1990. 85:25-32.) autonomic nervous system * brain-gut axis * calcitonin gene-related peptide * duodenal bicarbonate secretion * neuropeptides-vasopressin
Introduction
Duodenal bicarbonate secretion protects the mucosa against acid-peptic damage in humans and animals (1) (2) (3) (4) . Diminished proximal duodenal bicarbonate secretion at rest and in response to hydrochloric acid appears to be an important factor in the pathogenesis of duodenal ulcer disease (5) . Like most gut secretory processes, duodenal bicarbonate secretion is controlled by the autonomic nervous system. Stimulation of parasympathetic (vagal) efferents increases while stimulation of sympathetic (splanchnic) efferents decreases duodenal bicarbonate secretion (6, 7) . Corticotropin-releasing factor is an endogenous central nervous system transmitter that mediates stimulation of duodenal bicarbonate secretion during stress by release of 6-endorphin from the pituitary (8) . Thyrotropin-releasing hormone is a candidate central nervous system transmitter that stimulates gastric acid and duodenal bicarbonate secretion by increasing vagal outflow (9) . The central nervous system transmitter(s) that mediates inhibition of duodenal bicarbonate secretion in situations of increased noradrenergic activity is unknown.
We have recently screened 10 neuropeptides and tested their central nervous system effects on proximal duodenal bicarbonate secretion in awake, nonrestrained rats (10) . Calcitonin gene-related peptide (CGRP; 11)' was the only peptide that significantly inhibited proximal duodenal bicarbonate secretion (10) . This peptide selectively stimulates noradrenergic sympathetic outflow ( 12) and potently inhibits gastric acid secretion and gastrointestinal transit in rats and dogs (13) (14) (15) (16) (17) (18) (19) . The purposes ofthe present investigation were threefold: (a) to examine the pharmacological properties of CGRP to inhibit resting and stimulated duodenal bicarbonate secretion in awake, freely moving rats; (b) to determine the pathways that are involved in mediating the central nervous system effects of CGRP; and (c) to study the peripheral effects of presumed transmitters released by CGRP. Our results indicate that cerebroventricular CGRP inhibits resting and stimulated duodenal bicarbonate secretion by stimulation of noradrenergic sympathetic outflow and vasopressin release. They also demonstrate that the inhibitory effects ofperipheral NE and vasopressin on bicarbonate secretion are synergistic and mediated by specific alpha adrenergic and vasopressin receptors.
Methods
Male Sprague-Dawley rats (250-300 g) were used. The animals were housed in separate cages under illumination-, temperature-, and humidity-controlled conditions, and fed a standard rat diet before and a liquid diet after surgery. 4 mg/kg [Rompun, Bayer AG, Leverkusen, FRGJ). Paying particular attention to the integrity of surrounding pancreatic tissue and blood supply, the first 2 cm of the duodenum (proximal to the pancreatic duct) were isolated and the pylorus anastomosed to the distal duodenum by seven to eight single sutures. The proximal and distal ends of the isolated duodenal segment were connected with polyethylene catheters (PE-90) and secured by purse string sutures. The catheters then were routed subcutaneously to exit in the interscapular region of the animal's neck. They were closed with cut needle ends that served as connectors for catheters used to perfuse the duodenal segment and to collect duodenal perfusates. After surgery the segment was flushed every 8 h with 5 ml of 0. 15 M NaCi to remove duodenal mucus and maintain patency of the segment and catheters (8) .
During a second surgery (2-4 d before the experiment and 3-5 d after the intestinal surgery), a 22-gauge stainless steel cannula (Plastic Products Co., Roanoke, VA) was implanted using a stereotaxic instrument (David Kopf Instruments, Tujunga, CA) so that its tip was inside the right cerebral ventricle (20) . In each animal, correct cannula placement was verified by injection of methylene blue (20) . The animals were also fitted with a right jugular venous catheter (PE-50) that was routed subcutaneously to exit in the interscapular region of the animal's neck, where it was closed by a cut needle end and secured with adhesive tape (20) . In some animals, bilateral, truncal, subdiaphragmatic vagotomy, or adrenalectomy were performed as previously described (20) . Hypophysectomized animals were commercially obtained (Wiga, Sulzfeld, FRG). Completeness of adrenalectomy and hypophysectomy were documented by macroscopic inspection. To demonstrate completeness of vagotomy, a 2-deoxy-D-glucose test (100 mg/kg-3 min; Sigma Chemie GmbH, Deisenhofen, FRG) was performed (20) . Adrenalectomized and hypophysectomized animals had free access to 0.15 M NaCl.
On the day of the experiment the animals were placed into 15-liter buckets to which they were accustomed. They were fasted for 16 h but had free access to tap water until the beginning of the experiment. The cerebroventricular cannula was connected with a polyethylene catheter (PE-IO), the jugular vein catheter with PE-50, and the duodenal catheters with PE-90. The duodenal segment was constantly perfused with 0.15 M NaCl (390C, 30 ml/h) and the effluent collected at 15-min intervals in graduated cone vials. To clear the segment from residual mucus and secretions, the first four collections were discarded (8) . Rat CGRP and calcitonin ( 16) were injected cerebroventricularly or intravenously over I min in 10-Mul and 0.5-ml volumes, respectively (16) . Peptides were kindly provided by Dr. Jean E. Rivier (Salk Institute, La Jolla, CA), stored in Iyophylized form, and freshly dissolved in sterile water before each experiment. The vehicle, sterile water, served as control.
Bicarbonate concentrations of the duodenal effluent were measured by a validated back-titration method for low bicarbonate concentrations (2, 8) . Measurements were performed in triplicate. A 2-ml aliquot ofthe effluent was added to 5 ml ofCO2-free H20 and acidified with 125 ,l of 100 mM H2SO4. To remove any residual CO2, the solution was gassed for 5 min with N2 and washed with Ba(OH)2. The sample then was titrated by the addition of 15 (17) . Ganglion blockade of autonomic efferents was performed with chlorisondamine (3 mg/kg-h; Ecolid, Ciba-Geigy, Basal, Switzerland) (20) . Opiate receptor blockade was achieved with naloxone (I mg/kg. h; Sigma Chemie GmbH) (8) . Intravenous infusion of these agents was begun I h before bicarbonate measurements and 2 h before cerebroventricular injection of CGRP. Except for alpha adrenergic blockade with phentolamine, these pharmacological approaches were previously validated (8, 9, 15, 17, 19, 20) . The effectiveness of phentolamine in blocking the actions of NE on duodenal bicarbonate secretion was documented in this study.
Dose-response studies were performed with NE (5, 25, and 50 nmol/kg; Arterenol, Hoechst AG, Frankfurt, FRG) and (8-arginine)-vasopressin (0.05, 0.25, and 0.5 nmol/kg; provided by Dr. Jean E. Rivier). Each dose was given intreperitoneally on a separate day and in random order and the 30-45-min interval after injection (interval of greatest response) was used for analysis. In some experiments NE and vasopressin were given concomitantly. In other experiments phentolamine or the vasopressin antagonist were given intravenously as constant infusions before intraperitoneal administration of NE or vasopressin.
Venous blood was aspirated at times 0, 15, and 30 min for determination of plasma concentrations of epinephrine and NE (0.6 ml/sample) and vasopressin (1.2 ml/sample) in separate groups of animals. In additional experiments vasopressin (0.5 nmol/kg) and NE (50 nmol/ kg) were injected intraperitoneally and plasma concentrations of vasopressin and NE were determined before and 30 min after injection. Blood was replaced by equal volumes of 0.15 M NaCl. Blood was collected in chilled tubes, centrifuged at 3,000 g (4°C), and stored at -20°C. Plasma catecholamine concentrations were determined by a single isotope radioenzymatic method (22 (1 nmol) had no significant effect (Table I) .
Cerebroventricular administration of CGRP produced immediate and significant inhibition of duodenal bicarbonate secretion lasting 90 min (Fig. 2 A) . Pretreatment ofthe animals with a vasopressin receptor antagonist did not significantly alter resting duodenal bicarbonate secretion, but significantly attenuated the inhibitory effect of cerebroventricular CGRP (Fig. 2 A) . At the 30-, 45-, and 60-min time intervals, duodenal bicarbonate secretion was significantly (P < 0.05) greater in animals treated with CGRP and the vasopressin antagonist ( Fig. 2 B) than in animals treated with CGRP and NaCi as the control (Fig. 2 A) .
Pretreatment of the animals with the alpha adrenergic blocking agent, phentolamine, increased resting duodenal bicarbonate secretion from -12 to 21 Amol/cm h (-75%) (Fig. 2 C) . Phentolamine alone significantly (P < 0.05) attenuated the inhibitory effect of CGRP on duodenal bicarbonate secretion (Fig. 2 C) , while pretreatment of the animals with phentolamine and the vasopressin receptor antagonist abolished the inhibitory effect of cerebroventricular CGRP (Fig. 2  D) . The mean 2-h total bicarbonate outputs (±SE) in response to CGRP expressed as a percentage ofthe 2-h total bicarbonate outputs in response to the respective cerebroventricular controls were NaCl, 63±5%; vasopressin receptor antagonist, 81±6%; phentolamine, 81±5%; vasopressin receptor antagonist plus phentolamine, 95±4% (P < 0.01 each compared with NaCl).
To assure completeness of vagotomy, duodenal bicarbonate secretion was measured for 1 tylium did not (Fig. 3) . Chlorisondamine completely abolished and bretylium significantly (P < 0.01) attenuated inhibition of duodenal bicarbonate secretion induced by cerebroventricular CGRP (Fig. 3, A and B) . In contrast, truncal vagotomy did not attenuate the inhibitory effect of CGRP (Fig. 3 C) . total bicarbonate outputs in response to CGRP expressed as a percentage of the total 2-h bicarbonate outputs in response to the respective controls were: bretylium 84±5% and vagotomy 46±3%. These responses were significantly (P < 0.01) different from the response produced by CGRP in NaCl-treated animals (63±5%) (Fig. 2 A) .
As depicted in Figs. 2 and 3 , phentolamine, chlorisondamine, and truncal vagotomy altered the baseline of resting duodenal bicarbonate secretion. To compare the relative effects of these pharmacological and surgical procedures on CGRP-induced inhibition of duodenal bicarbonate secretion, the effects of CGRP were expressed as a percentage of the bicarbonate responses of the appropriate control experiments. The maximal inhibitory effect of CGRP was observed during the third collection interval (30-45 min) after cerebroventricular administration. Therefore, this interval was chosen for comparison. In control animals (no pharmacological pretreatment or surgery) CGRP decreased the bicarbonate response to 37±5% (Fig. 4) . Vagotomy significantly (P < 0.05) enhanced (Fig. 4) . Combined treatment with phentolamine and the vasopressin receptor antagonist or ganglionic blockade with chlorisondamine reversed the inhibitory effect of cerebroventricular CGRP on duodenal bicarbonate secretion (Fig. 4) .
Hypophysectomy, adrenalectomy, and opiate blockade with naloxone did not significantly alter resting bicarbonate secretion or attenuate the inhibitory effects of CGRP (Table  II) . Cerebroventricular administration of CGRP (1 nmol) significantly increased plasma concentrations of vasopressin and NE (Fig. 5) but not of epinephrine (data not shown).
Intraperitoneal administration of increasing doses of vasopressin and NE produced dose-dependent inhibition of duodenal bicarbonate secretion (Fig. 6 ). Of note, on a molar basis vasopressin appeared to be -100 times more potent and effective than NE in inhibiting bicarbonate secretion in vivo. The vasopressin receptor antagonist and the alpha adrenergic antagonist, phentolamine, abolished the effects of exogenous vasopressin and NE on bicarbonate secretion, respectively (Fig. 6 ). Intraperitoneal administration of vasopressin (0.25 nmol/kg) and NE (25 nmol/kg) given concomitantly inhibited duodenal bicarbonate secretion by 63±4%, while vasopressin and NE given separately inhibited the bicarbonate response by 33±2 and 29±3%, respectively (Fig. 6 ). Combined treatment with intraperitoneal vasopressin and NE produced inhibition of duodenal bicarbonate secretion that was similar to the response observed after a maximal dose of cerebroventricular CGRP (5 nmol/kg) (Fig. 6) . Pretreatment of the animals with the vasopressin receptor antagonist and phentolamine completely reversed the inhibitory effect produced by intraperitoneal administration of vasopressin and NE (Fig. 6) .
To evaluate if the exogenously administered doses of vasopressin and NE produced similar plasma concentrations that were observed after cerebroventricular administration of CGRP, the highest doses that were used in the bioassay were given intraperitoneally. Vasopressin (0.5 nmol/kg) and NE (50 nmol/kg) significantly (P < 0.05) increased plasma vasopressin and NE concentrations (Table III) . While vasopressin administration produced plasma vasopressin concentrations that were similar to those observed in response to cerebroventricular administration of CGRP (at 30 min), NE administration produced plasma NE concentrations that were significantly (P < 0.05) less than those observed after cerebroventricular administration of CGRP (Table III , Fig. 5 ).
Discussion
Like most gut secretory processes, duodenal mucosal bicarbonate secretion is under the control ofthe autonomic nervous system. Stimulation of parasympathetic (vagal) efferents increases, while stimulation of sympathetic (splanchnic) efferents decreases duodenal bicarbonate secretion in a number of species (6, 7, 26, 27) . The central nervous system transmitters that promote these responses are largely unknown. We have recently provided evidence that thyrotropin-releasing hormone is a candidate neurotransmitter that stimulates duodenal bicarbonate secretion by increasing vagal outflow (9) . To the best of our knowledge, CGRP is the only oligopeptide to date that acts centrally to inhibit duodenal bicarbonate secretion (10) . This study examined the central nervous system effects of CGRP on proximal duodenal bicarbonate secretion in a newly developed animal model that permits measurement of duodenal bicarbonate secretion in freely moving animals (8) .
Intravenous administration of the gastrointestinal peptides neurotensin and VIP and intraluminal perfusion of the duodenum with a PGEI analogue and HCl increased bicarbonate secretion, extending previous observations in restrained or anesthetized rats (2, (28) (29) (30) , conscious dogs (4), and humans (1) . Intraluminal PGs and circulating neurotensin and VIP stimulate duodenal bicarbonate secretion by distinct mechanisms (4, 28-30) and intraluminal HCO stimulates bicarbonate secretion via a PG-and VIP-dependent mechanism (2, 30) . Therefore, the peripheral transmitters (i.e., NE and vasopressin) released in response to cerebroventricular CGRP probably interfere with each of these mechanisms.
Cerebroventricular administration of CGRP produced dose-dependent and long-lasting inhibition of resting (basal) bicarbonate secretion, while intravenous administration of CGRP exhibited a transient inhibitory effect. The peripheral effect of CGRP on bicarbonate secretion may be secondary to the peptide's pronounced peripheral hypotensive effect since the marked decrease in mean arterial pressure in an earlier study (12) peptide action after central and peripheral administration also suggest differences in site of action; i.e., cerebroventricular CGRP acts within the central nervous system, while intravenous CGRP acts at a peripheral, as yet unidentified site (15) . While the central nervous system effects of CGRP and calcitonin on gastric acid secretion and gastrointestinal transit are similar (16, 17, 19, 31) , unlike CGRP, calcitonin does not inhibit duodenal bicarbonate secretion. This observation suggests that rat calcitonin is not a ligand for the cerebral CGRP receptor (32, 33) involved in mediating the peptide's effect on duodenal bicarbonate secretion. Distinct receptors for CGRP and calcitonin have also been implicated in mediating the inhibitory effects of these two peptides on gastric acid secretion and gastrointestinal transit (19, 31) . However, the precise cerebral site of action of CGRP to inhibit duodenal bicarbonate secretion remains to be elucidated.
To determine the pathways that mediate the inhibitory effects of cerebroventricular CGRP surgical and pharmacological procedures were used. Ganglionic blockade and truncal vagotomy significantly decreased resting bicarbonate secretion, suggesting that parasympathetic efferents not only stimulate (6, 26, 27 ) but also exert a tonic effect on proximal duodenal bicarbonate secretion. In contrast, blockade of vasopressin and opiate receptors using specific antagonists, and preventing the release of NE from adrenergic nerve endings with bretylium, as well as adrenalectomy and hypophysectomy, did not significantly alter resting duodenal bicarbonate secretion, suggesting that none ofthese pathways is involved in (7) .
The observation that ganglionic blockade with chlorisondamine abolished the inhibitory effect of CGRP indicates that autonomic efferents are involved. This finding also suggests that ganglionic blockade affects both the noradrenergic and vasopressin-sensitive pathways that mediate the inhibitory effects of CGRP. Of interest, hypophysectomy did not prevent the inhibitory effects of CGRP on bicarbonate secretion, suggesting that nonpituitary vasopressin is released by cerebroventricular administration of CGRP. A vasopressin-like peptide has been identified in the mammalian sympathetic nervous system, including in the principal noradrenergic neurones of ganglia and in nerve fibers innervating peripheral tissues (36) . These findings support the contention that CGRP may corelease NE and vasopressin from sympathetic neuronal fibers rather than from the adrenal glands, since adrenalectomy did not alter the duodenal inhibitory effect of CGRP. However, the precise site of CGRP-induced vasopressin release remains to be determined.
Inhibition of gastric acid secretion and gastrointestinal transit induced by cerebroventricular administration ofCGRP appears to be mediated by parasympathetic (vagal) efferent fibers and not by noradrenergic efferents (13, 17, 19) . In this study vagotomy did not attenuate the inhibitory effect of CGRP on duodenal bicarbonate secretion. In addition, loss of vagal control further accentuated the inhibitory effect of CGRP, suggesting that removal of vagal transmitters facilitated inhibition of bicarbonate secretion induced by increased noradrenergic drive. Conversely, cerebroventricular corticotropin-releasing factor inhibits gastric acid secretion predominantly by increasing sympathetic outflow (20, 37) , but modulates intestinal transit by altering parasympathetic outflow (38) .
The physiological importance of CGRP increasing sympathetic outflow and thereby regulating duodenal bicarbonate secretion is unknown. Hemorrhagic shock decreases duodenal bicarbonate secretion and produces mucosal damage (39) . Furthermore, hemorrhage-induced hyposecretion ofduodenal bicarbonate is mediated by activation of sympathetic nerves (40) . Therefore, it is tempting to speculate that under these conditions CGRP may serve as an endogenous central nervous system mediator.
In summary, the results of this study indicate that CGRP acts within the central nervous system to inhibit resting and stimulated proximal duodenal bicarbonate secretion in awake, nonrestrained rats. CGRP exerts this action by enhancing sympathetic, noradrenergic outflow that results in release of NE and possibly nonpituitary vasopressin released from adrenergic nerve endings. NE and vasopressin inhibit duodenal bicarbonate secretion via specific noradrenergic and vasopressin receptors, respectively, and their inhibitory effects are additive.
